Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corporation (NYSE: ENOV) is described in its public materials as an innovation-driven medical technology growth company with a focus on orthopedics, musculoskeletal care and clinically differentiated solutions. The Enovis news stream on this page highlights how the company communicates with the market through earnings announcements, portfolio updates and participation in major healthcare and investor conferences.
Investors following ENOV news will see quarterly financial results releases, where Enovis reports performance for its Prevention & Recovery (P&R) and Reconstructive (Recon) segments and discusses trends such as organic sales growth, adjusted EBITDA and adjusted net income. These updates often include management commentary on commercial execution, innovation priorities, operational discipline and financial outlook.
Company news also covers strategic and portfolio actions, such as the sale of a diabetic footcare business from the Prevention & Recovery segment, which Enovis has described as sharpening its focus on core strengths in P&R. In addition, releases may address changes in leadership roles and organizational structure, reflecting how the company supports its next phase of growth and operational efficiency.
Another key element of Enovis-related news involves investor relations activities, including announcements about conference presentations, fireside chats and webcasts at healthcare and growth conferences, as well as participation in events like the J.P. Morgan Healthcare Conference. These items typically provide webcast details and indicate how investors can access presentations and replays.
For anyone researching ENOV, this news page offers a centralized view of the company’s earnings releases, strategic updates and investor event participation. It is a useful resource for tracking how Enovis describes its progress in medical technology, orthopedics and its Prevention & Recovery and Reconstructive businesses over time.
Enovis Corporation (NYSE: ENOV) has acquired Insight Medical Systems, enhancing its reconstructive portfolio with the FDA-cleared ARVIS® augmented reality surgical guidance technology. This acquisition aims to improve patient outcomes in hip and knee replacements. The ARVIS® system, already in use for over 200 cases in the U.S., offers real-time, hands-free guidance and is expected to be commercially available in Q3 2022. Enovis anticipates further growth and innovation by integrating this technology into its surgical business.
Enovis Corporation (NYSE: ENOV) announced the appointment of Ben Berry as the new Chief Financial Officer, effective January 1, 2023. Berry succeeds Chris Hix, who will transition to an advisory role until his retirement later in 2023. CEO Matt Trerotola praised Berry for his financial leadership and contributions to the company's growth strategy and improved operational performance since joining in 2020. Hix has played a pivotal role in transforming Enovis into a specialized medical technology leader since 2016.
Enovis Corporation (NYSE:ENOV) has unveiled the new Arsenal Ankle Plating System™, expanding its product line with 37 anatomically designed plates across nine families. This innovative system addresses both tri-malleolar and intra-articular fractures, enhancing the company's offerings in the ankle and foot market. The Arsenal System incorporates advanced technologies such as variable angle locking and multi-lock functionality to improve surgical outcomes. The launch reinforces Enovis' commitment to driving growth through differentiated medical solutions.
Enovis Corporation (NYSE: ENOV) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. CEO Matt Trerotola and CFO Chris Hix will engage with investors at the event in Rancho Palos Verdes, California. The company, previously known as Colfax Corporation, focuses on innovative medical technology aimed at improving patient outcomes and transforming healthcare workflows.
For more details, visit www.enovis.com.
Enovis Corporation (NYSE: ENOV) reported strong first-quarter 2022 results, with sales of $375 million, a 21% increase year-over-year, and 7% organic growth. Reconstructive sales surged 72% to $131 million, while Prevention and Recovery sales rose 4% to $245 million. Adjusted EBITDA grew 25% to $48 million, with a margin of 12.7%. After spinning off ESAB Corporation, Enovis now has no net leverage. The company maintains its full-year guidance, projecting revenue growth of 10% to 14% and adjusted EPS of $2.20 to $2.40.
Enovis Corporation (NYSE: ENOV), an innovative medical technology company, announced it will release pro forma financial results for Q1 FY2022 on May 10, 2022. A public conference call will follow at 8:00 a.m. Eastern, where company officials will discuss the results. Interested parties can join the call by phone or through a webcast on Enovis’ website. The event aims to provide insights into the company's performance and strategies for growth.